Heard at the Roundtable

• Clyde Yancy, MD:

  "The treatment of those affected with heart failure remains suboptimal, with gaps in care now extensively documented by a number of outcomes services researchers. ... This is abysmally poor and requires a renewed quality focused effort. "

  View Full Roundtable:Commentary - The Treatment of Heart Failure 
in African Americans

• Jonathan Halperin, MD:

  "I think the strongest argument in favor of making the change, is that results in clinical trials of all of the new drugs that have thus far been reported offer substantial reductions in the risk of intracerebral hemorrhage."

  View Full Roundtable:The Role of and Selection Process 
for the New Anticoagulants in 
Nonvalvular Atrial Fibrillation

• Charles Hennekens, MD:

  "Patients with MetS and high triglycerides are the most liekly to develop diabetes in the relatively near future.  All patients with MetS, especially those with high triglycerides, need to be treated aggressively with TLCs and adjunctive drug therapies of proven benefit."

  View Full Roundtable: Metabolic Syndrome: The New Silent Killer

• Michael Davidson, MD:

  “I think it is unfortunate that ezetimibe has been approved and available for 10 years and there are still doubts about its clinical benefit on reducing cardiovascular events.”

  View Full Roundtable:What Recent Trials Have Taught Us About the Efficacy of Ezetimibe

• Stephen Devries, MD:

  "The Lyon Mediterranean Diet Study had a 70% reduction in cardiac events—a benefit that exceeded that of most drug trials."

  View Full Roundtable:The Mediterranean Diet